HC Wainwright Reaffirms “Buy” Rating for Aquestive Therapeutics (NASDAQ:AQST)

HC Wainwright restated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report published on Wednesday morning, Benzinga reports. They currently have a $10.00 price objective on the stock.

AQST has been the subject of several other research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Leerink Partners upped their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $8.83.

Aquestive Therapeutics Stock Performance

NASDAQ AQST opened at $5.07 on Wednesday. Aquestive Therapeutics has a 52-week low of $1.55 and a 52-week high of $6.23. The company has a fifty day moving average of $4.91 and a 200-day moving average of $3.83. The company has a market capitalization of $461.67 million, a P/E ratio of -11.27 and a beta of 2.82.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same period in the prior year, the business posted ($0.03) earnings per share. As a group, analysts forecast that Aquestive Therapeutics will post -0.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Financial Advocates Investment Management raised its holdings in Aquestive Therapeutics by 14.7% during the 3rd quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock valued at $194,000 after buying an additional 5,000 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Aquestive Therapeutics during the third quarter valued at about $28,000. SG Americas Securities LLC boosted its holdings in shares of Aquestive Therapeutics by 58.9% during the third quarter. SG Americas Securities LLC now owns 25,619 shares of the company’s stock worth $128,000 after purchasing an additional 9,496 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Aquestive Therapeutics in the second quarter worth about $27,000. Finally, PFG Investments LLC grew its stake in shares of Aquestive Therapeutics by 22.9% in the second quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock worth $153,000 after purchasing an additional 11,000 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.